Yes, a specific myostatin-targeting medicine now has a U.S. approval: Isembyld (apitegromab-mstn). Its September 2026 indication is SMA in adults and children aged 2 years or older who are currently receiving an SMN2-targeted treatment.[1][2]
- U.S. medicine
- Isembyld
- Approval date
- September 11, 2026
- Records checked
- October 10, 2026
What changed in September 2026?
The FDA approved apitegromab-mstn on September 11, 2026. It is a monoclonal antibody targeting myostatin proforms, rather than a generic category of research peptides.[2][3]
Older pages may still state that no myostatin inhibitor is approved. Dates matter here. Use the official approval record and current label instead of relying on a general article written before the decision.
What does the approval cover?
Read the full indication, not just the word “approved.” The medicine, disease, age range, and background treatment define the claim. Approval for this SMA population does not establish an approved bodybuilding use or approval of a differently manufactured substance.
The FDA announcement describes the clinical evidence, while the label supplies the formal prescribing information. Both are useful, and neither should be replaced by a seller’s interpretation.
| Detail | Current approval context |
|---|---|
| Medicine | Isembyld / apitegromab-mstn |
| Condition | Spinal muscular atrophy |
| Age | 2 years or older, including adults |
| Background therapy | Currently receiving an SMN2-targeted treatment |
Does “research use only” mean FDA-approved?
No. Research-use wording is not an approval document. FDA’s 2024 Summit Research Peptides warning letter explains why such wording did not overcome evidence of intended human use for the products named in that letter.[4]
A lab report, a reference to a registered facility, or a scientific-looking product page also does not substitute for an approval record. Ask for the exact medicine and the official record supporting the claim.
How should you verify a claim now?
Check the current FDA-hosted label and approval letter. Match the name and formulation, then read the indication and safety information. Do not assume that one product’s approval transfers to another substance sharing part of its mechanism.
If a treatment decision is involved, ask a qualified clinician to explain how the official indication and evidence relate to your situation. This page describes the U.S. records checked on October 10, 2026; regulatory status elsewhere may differ.
Questions, answered.
Are all myostatin inhibitor peptides approved now?
No. A specific medicine’s approval does not approve a broad category, unrelated compounds, or retail research preparations.
Is apitegromab approved for bodybuilding?
The cited FDA indication is SMA with the specified age and background-treatment requirements. It is not a bodybuilding indication.
Sources & further reading
Primary research and official records used for this page. Study results apply to the populations and interventions described.
- FDA Approves First Therapy to Target Muscle Loss in Spinal Muscular AtrophyU.S. Food and Drug Administration · September 2026 · Official approval announcement
- Isembyld (apitegromab-mstn) prescribing informationFDA-hosted prescribing information · Revised September 2026 · PDF
- Isembyld approval letterU.S. Food and Drug Administration · September 11, 2026 · PDF
- Summit Research Peptides — FDA warning letter 695607U.S. Food and Drug Administration · December 10, 2024 · Named GLP-1-related products